Dyne Therapeutics Announces Upcoming Presentations at the 2025 MDA Clinical & Scientific Conference

Core Insights - Dyne Therapeutics will present data from its ongoing DELIVER and ACHIEVE clinical trials at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference, highlighting advancements in targeted therapeutics for neuromuscular diseases [1][5] Group 1: Presentations - The company will conduct two oral presentations on March 19, 2025, focusing on the DELIVER trial for Duchenne muscular dystrophy (DMD) and the ACHIEVE trial for myotonic dystrophy type 1 (DM1) [2] - The DELIVER trial presentation will cover safety and efficacy data for DYNE-251 in males with DMD mutations amenable to exon 51 skipping [2] - The ACHIEVE trial presentation will discuss safety and efficacy data for DYNE-101 in adults with DM1 [2] Group 2: Symposium and Platform - A symposium titled "Harnessing the FORCE™ Platform to Advance Targeted Therapies for Neuromuscular Diseases" will take place on March 18, 2025, detailing the platform's capabilities and data from the lead clinical programs in DM1 and DMD [5] - The FORCE™ platform is designed to deliver targeted therapeutics to muscle and the central nervous system (CNS), showcasing its potential in treating genetically driven neuromuscular diseases [6] Group 3: Conference Details - The MDA conference will feature poster presentations from March 16 to March 18, 2025, providing additional insights into Dyne's research and clinical programs [3][4]